Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,007 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 31,007 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 750 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse/Cust Son | 400 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 400 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 1,000 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 18, 2021 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $658.79 | $1,317,580.00 |
DisclosureSEC source: 0001237899-21-000024 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,858 Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $650.00 | $1,300,000.00 |
DisclosureSEC source: 0001237899-21-000024 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,858 Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $672.00 | $201,600.00 |
DisclosureSEC source: 0001237899-21-000020 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 1,750 Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 250 | $670.00 | $167,500.00 |
DisclosureSEC source: 0001237899-21-000020 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 750 Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $675.00 | $337,500.00 |
DisclosureSEC source: 0001237899-21-000020 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,858 Read SEC document |
| August 30, 2021 Filed Aug 30, 2021 20:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $670.00 | $335,000.00 |
DisclosureSEC source: 0001237899-21-000020 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,358 Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 150 | $672.00 | $100,800.00 |
DisclosureSEC source: 0001237899-21-000020 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 1,000 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $627.50 | $627,500.00 |
DisclosureSEC source: 0001237899-21-000016 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 2,050 F1 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on August 16, 2021 at prices ranging from $627.37 to $627.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 705 | $630.00 | $444,150.00 |
DisclosureSEC source: 0001237899-21-000016 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,858 Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $620.00 | $310,000.00 |
DisclosureSEC source: 0001237899-21-000014 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,563 Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $611.00 | $611,000.00 |
DisclosureSEC source: 0001237899-21-000014 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,063 Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $620.00 | $186,000.00 |
DisclosureSEC source: 0001237899-21-000014 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 3,050 Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $621.00 | $621,000.00 |
DisclosureSEC source: 0001237899-21-000014 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,063 Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $620.00 | $620,000.00 |
DisclosureSEC source: 0001237899-21-000014 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,063 Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $613.01 | $613,010.00 |
DisclosureSEC source: 0001237899-21-000011 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,063 F1 · price: Represents volume-weighted average price of sales of 1,000 shares of Company stock on August 10, 2021 at prices ranging from $613.00 to $613.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 10, 2021 at each separate price. Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $614.00 | $614,000.00 |
DisclosureSEC source: 0001237899-21-000011 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,063 Read SEC document |
| August 10, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 600 | $615.00 | $369,000.00 |
DisclosureSEC source: 0001237899-21-000011 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,063 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 350 | $612.42 | $214,347.00 |
DisclosureSEC source: 0001237899-21-000011 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 3,350 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $611.23 | $611,230.00 |
DisclosureSEC source: 0001237899-21-000011 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,663 Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $611.43 | $1,834,290.00 |
DisclosureSEC source: 0001237899-21-000011 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,663 Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:32 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001237899-21-000003 · edgardoc.xml · derivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:32 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-21-000003 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,663 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,900 | $614.51 | $1,167,569.00 |
DisclosureSEC source: 0001237899-20-000038 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,415 F5 · price: Represents volume-weighted average price of sales of 1,900 shares of Company stock on August 31, 2020 at prices ranging from $614.01 to $614.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,100 | $613.54 | $674,894.00 |
DisclosureSEC source: 0001237899-20-000038 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,315 F4 · price: Represents volume-weighted average price of sales of 1,100 shares of Company stock on August 31, 2020 at prices ranging from $613.00 to $613.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $612.27 | $1,224,540.00 |
DisclosureSEC source: 0001237899-20-000038 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,415 F3 · price: Represents volume-weighted average price of sales of 2,000 shares of Company stock on August 31, 2020 at prices ranging from $612.05 to $612.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,400 | $611.38 | $855,932.00 |
DisclosureSEC source: 0001237899-20-000038 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,415 F2 · price: Represents volume-weighted average price of sales of 1,400 shares of Company stock on August 31, 2020 at prices ranging from $611.13 to $611.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. Read SEC document |
| August 31, 2020 Filed Aug 31, 2020 20:36 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,600 | $610.45 | $2,197,620.00 |
DisclosureSEC source: 0001237899-20-000038 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,815 F1 · price: Represents volume-weighted average price of sales of 3,600 shares of Company stock on August 31, 2020 at prices ranging from $610.05 to $610.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,750 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · derivative · entry 20 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,750 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,000 | $612.00 | $612,000.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 17 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 3,700 Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $614.15 | $184,245.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 16 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,415 F14 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on August 25, 2020 at prices ranging from $614.01 to $614.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $613.39 | $490,712.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 15 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,715 F13 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on August 25, 2020 at prices ranging from $613.07 to $613.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,900 | $612.43 | $1,163,617.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 14 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,515 F12 · price: Represents volume-weighted average price of sales of 1,900 shares of Company stock on August 25, 2020 at prices ranging from $612.09 to $612.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,840 | $611.60 | $2,348,544.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 13 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,415 F11 · price: Represents volume-weighted average price of sales of 3,840 shares of Company stock on August 25, 2020 at prices ranging from $611.14 to $611.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,793 | $610.42 | $2,315,323.06 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 12 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,255 F10 · price: Represents volume-weighted average price of sales of 3,793 shares of Company stock on August 25, 2020 at prices ranging from $610.00 to $610.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 760 | $609.67 | $463,349.20 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 11 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,048 F9 · price: Represents volume-weighted average price of sales of 760 shares of Company stock on August 25, 2020 at prices ranging from $609.15 to $609.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $608.06 | $182,418.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 10 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,808 Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,384 | $607.46 | $1,448,184.64 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 9 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,108 F8 · price: Represents volume-weighted average price of sales of 2,384 shares of Company stock on August 25, 2020 at prices ranging from $607.13 to $607.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,168 | $606.43 | $3,134,030.24 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 8 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,492 F7 · price: Represents volume-weighted average price of sales of 5,168 shares of Company stock on August 25, 2020 at prices ranging from $606.05 to $606.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,700 | $605.53 | $2,845,991.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,660 F6 · price: Represents volume-weighted average price of sales of 4,700 shares of Company stock on August 25, 2020 at prices ranging from $605.00 to $605.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,705 | $604.43 | $2,239,413.15 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 6 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,360 F5 · price: Represents volume-weighted average price of sales of 3,705 shares of Company stock on August 25, 2020 at prices ranging from $604.00 to $604.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,000 | $603.53 | $1,810,590.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 5 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,065 F4 · price: Represents volume-weighted average price of sales of 3,000 shares of Company stock on August 25, 2020 at prices ranging from $603.02 to $603.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $602.68 | $241,072.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 4 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,065 F3 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on August 25, 2020 at prices ranging from $602.05 to $602.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $601.75 | $180,525.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 3 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,465 F2 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on August 25, 2020 at prices ranging from $601.64 to $601.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,400 | $600.36 | $840,504.00 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 2 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,765 F1 · price: Represents volume-weighted average price of sales of 1,400 shares of Company stock on August 25, 2020 at prices ranging from $600.04 to $600.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 25, 2020 at each separate price. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 12,750 | $273.67 | $3,489,292.50 |
DisclosureSEC source: 0001708138-20-000102 · edgardoc.xml · nonDerivative · entry 1 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,037 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001708138-20-000098 · edgardoc.xml · derivative · entry 7 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,037 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. F2 · derivative.underlying_shares: Form two of two Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 136 | $593.23 | $80,679.28 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 30 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,415 F25 · price: Represents volume-weighted average price of sales of 136 shares of Company stock on August 24, 2020 at prices ranging from $593.06 to $593.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. F26 · balance_after: Form one of two Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,626 | $592.28 | $3,332,167.28 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 29 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,551 F24 · price: Represents volume-weighted average price of sales of 5,626 shares of Company stock on August 24, 2020 at prices ranging from $592.00 to $592.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 135 | $597.93 | $80,720.55 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 28 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,177 F23 · price: Represents volume-weighted average price of sales of 135 shares of Company stock on August 24, 2020 at prices ranging from $597.68 to $598.02. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 22:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,303 | $596.56 | $777,317.68 |
DisclosureSEC source: 0001708138-20-000097 · edgardoc.xml · nonDerivative · entry 27 SING GEORGE L · CIK 0001225471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,312 F22 · price: Represents volume-weighted average price of sales of 1,303 shares of Company stock on August 24, 2020 at prices ranging from $596.15 to $596.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 24, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.